Loading...

Vita Life Sciences Limited

VLS.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
A$2.38
A$0.00(0.00%)

Vita Life Sciences Limited VLS.AX Peers

See (VLS.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
VLS.AXA$2.38+0.00%129.6M14.87A$0.16+4.20%
CAU.AXA$0.54+0.00%300.5M-16.88-A$0.03N/A
AFP.AXA$2.43+2.97%254.8M24.30A$0.10+0.69%
PBP.AXA$2.98-0.33%242.3M29.80A$0.10N/A
LV1.AXA$0.92+0.00%144.1M3.05A$0.30N/A
IHL.AXA$0.04-10.87%65.1M-0.03-A$1.30N/A
MVP.AXA$0.55+1.85%62M-1.62-A$0.34N/A
ANP.AXA$0.06-4.92%52.3M-2.90-A$0.02N/A
VIT.AXA$0.06+0.00%41.1M6.20A$0.01N/A
IDT.AXA$0.09-1.11%37.6M-8.90-A$0.01N/A
Showing 1 to 10 of 29 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

VLS.AX vs CAU.AX Comparison

VLS.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VLS.AX stands at 129.6M. In comparison, CAU.AX has a market cap of 300.5M. Regarding current trading prices, VLS.AX is priced at A$2.38, while CAU.AX trades at A$0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VLS.AX currently has a P/E ratio of 14.87, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, VLS.AX's ROE is +0.17%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, VLS.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for VLS.AX.

Stock Price Comparison

Loading...

Frequently Asked Questions

;